Skip to main content
SpringerLink
Log in

Contraception and Menstrual Suppression for Adolescent and Young Adult Oncology Patients

  • Chapter
  • First Online:
Pediatric and Adolescent Oncofertility

  • 599 Accesses

Abstract

According to the 2013 National Youth Risk Behavior Survey [1], 47 % of high school students in the United States (USA) admitted to previous sexual intercourse, and of those, 14 % did not use any method of pregnancy prevention [1]. An unintended pregnancy during cancer treatments may result in delay in therapy, teratogenic exposure, and/or pregnancy termination [2]. For many of these patients, unintended pregnancy is associated with an unacceptable health risk. Therefore, an open and early discussion about contraceptive needs and options is essential to the overall care of the adolescent and young adult oncology patient. Choosing a contraceptive method is an important decision with many involved factors for both patients and physicians. We must consider the efficacy and safety profile of each method, as well as how the method fits into each patient’s lifestyle, including technical, social, and religious factors, among others. In the adolescent oncology patient, these issues can compound quickly. Medically, these patients’ present increased challenges due to their underlying diagnoses and the increased risk of thrombotic disease associated with all malignancy. A thorough discussion of indicated contraceptive methods should be undertaken with each patient, with focus placed on efficacy and safety. An added benefit (or alternative use) of contraceptive medications during cancer treatment has been to elicit menstrual lightening and suppression, especially in patients with low blood count, menorrhagia, and/or risk of bone marrow suppression. Additionally, every social situation is unique and we must remember to ensure confidentiality in our adolescent patients seeking sexual health counseling and contraception.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brener ND, Kann L, Shanklin S, et al. Methodology of the youth risk behavior surveillance system – 2013. MMWR Recomm Rep (Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control). 2013;62(RR-1):1–20.

    Google Scholar 

  2. Committee Opinion No. 607: Gynecologic concerns in children and adolescents with cancer. Obstet Gynecol. 2014;124(2 Pt 1):403–8.

    Google Scholar 

  3. WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available at http://apps.who.int/iris/bitstream/10665/172915/1/WHO_RHR_15.07_eng.pdf.

  4. Patel A, Schwarz EB. Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception. 2012;86(3):191–8.

    Article  PubMed  Google Scholar 

  5. Lindberg LD, Maddow-Zimet I. Consequences of sex education on teen and young adult sexual behaviors and outcomes. J Adolesc Health Off Publ Soc Adolesc Med. 2012;51(4):332–8.

    Article  Google Scholar 

  6. Kohler PK, Manhart LE, Lafferty WE. Abstinence-only and comprehensive sex education and the initiation of sexual activity and teen pregnancy. J Adolesc Health Off Publ Soc Adolesc Med. 2008;42(4):344–51.

    Article  Google Scholar 

  7. Mueller TE, Gavin LE, Kulkarni A. The association between sex education and youth’s engagement in sexual intercourse, age at first intercourse, and birth control use at first sex. J Adolesc Health Off Publ Soc Adolesc Med. 2008;42(1):89–96.

    Article  Google Scholar 

  8. Committee Opinion No. 582: addressing health risks of noncoital sexual activity. Obstet Gynecol. 2013;122(6):1378–82.

    Google Scholar 

  9. Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS. Contraceptive technology. 20th ed. Ardent Media Inc., New York, NY 2011.

    Google Scholar 

  10. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115(1):206–18.

    Google Scholar 

  11. Sorensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab. 2010;95(1):263–70.

    Article  PubMed  Google Scholar 

  12. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep (Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control). 2010;59(RR-4):1–86.

    Google Scholar 

  13. Black A, Francoeur D, Rowe T, et al. Canadian contraception consensus. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2004;26(4):347–87. 89–436.

    Google Scholar 

  14. Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics. 1994;94(5):687–94.

    CAS  PubMed  Google Scholar 

  15. Committee Opinion No. 602: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123(6):1398–402.

    Google Scholar 

  16. Lopez LM, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2013;7:CD008815.

    PubMed Central  Google Scholar 

  17. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160(1):40–5.

    Article  PubMed  Google Scholar 

  18. Bonny AE, Lange HL, Rogers LK, Gothard DM, Reed MD. A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. Contraception. 2014;89(5):357–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Committee Opinion No. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120(4):983–8.

    Google Scholar 

  20. Secura GM, Madden T, McNicholas C, et al. Provision of no-cost, long-acting contraception and teenage pregnancy. N Engl J Med. 2014;371(14):1316–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011;84(5):493–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to long-acting reversible contraceptive (LARC) use in adolescents. J Adolesc Health Off Publ Soc Adolesc Med. 2013;52(4 Suppl):S59–63.

    Article  Google Scholar 

  23. Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120(6):1298–305.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception. 2009;79(6):418–23.

    Article  PubMed  Google Scholar 

  25. McNicholas C, Peipert JF. Long-acting reversible contraception for adolescents. Curr Opin Obstet Gynecol. 2012;24(5):293–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–53.

    Article  PubMed  Google Scholar 

  27. Heinemann K, Reed S, Moehner S, Do Minh T. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015;91(4):274–9.

    Article  CAS  PubMed  Google Scholar 

  28. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–8.

    Article  CAS  PubMed  Google Scholar 

  29. Dean G, Goldberg AB. Intrauterine contraception (IUD): overview. 2014. http://www.uptodate.com/contents/intrauterine-contraception-iud-overview?source=search_result&search=Intrauterine+contraception+%28IUD%29%3A+Overview&selectedTitle=1%7E150.

  30. ACOG Practice Bulletin No. 112: emergency contraception. Obstet Gynecol. 2010;115(5):1100─9.

    Google Scholar 

  31. Zieman M. Emergency contraception. 2014. http://www.uptodate.com/contents/emergency-contraception?source=search_result&search=Emergency+contraception&selectedTitle=1%7E137.

  32. ACOG Committee Opinion Number 542: Access to emergency contraception. Obstet Gynecol. 2012;120(5):1250–3.

    Google Scholar 

  33. Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):3–8.

    Article  PubMed  Google Scholar 

  34. Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107(7):1634–41.

    Article  CAS  PubMed  Google Scholar 

  35. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. Hum Reprod. 1994;9(9):1618–25.

    CAS  PubMed  Google Scholar 

  36. Divasta AD, Laufer MR, Gordon CM. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol. 2007;20(5):293–7.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80(2):113–8.

    Article  CAS  PubMed  Google Scholar 

  38. Committee Opinion No. 606: options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Obstet Gynecol. 2014;124(2 Pt 1):397–402.

    Google Scholar 

  39. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101(4):653–61.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric & Adolescent Gynecology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Janie Benoit MD & Holly Hoefgen MD

Authors
  1. Janie Benoit MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holly Hoefgen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holly Hoefgen MD .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA

    Teresa K. Woodruff

  2. Northwestern University, Chicago, Illinois, USA

    Yasmin C. Gosiengfiao

Appendix: Medical Eligibility Criteria for Contraceptive Use

Appendix: Medical Eligibility Criteria for Contraceptive Use

PDF file saved as MEC Appendix A

figure a
figure b

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Benoit, J., Hoefgen, H. (2017). Contraception and Menstrual Suppression for Adolescent and Young Adult Oncology Patients. In: Woodruff, T., Gosiengfiao, Y. (eds) Pediatric and Adolescent Oncofertility. Springer, Cham. https://doi.org/10.1007/978-3-319-32973-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32973-4_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32971-0

  • Online ISBN: 978-3-319-32973-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation